U.S. Markets close in 6 hrs 17 mins
  • S&P 500

    -7.12 (-0.17%)
  • Dow 30

    -121.78 (-0.36%)
  • Nasdaq

    -21.45 (-0.15%)
  • Russell 2000

    +5.60 (+0.25%)
  • Crude Oil

    +0.16 (+0.25%)
  • Gold

    -8.10 (-0.46%)
  • Silver

    -0.25 (-0.98%)

    +0.0050 (+0.4211%)
  • 10-Yr Bond

    +0.0320 (+2.03%)
  • Vix

    +0.62 (+3.74%)

    +0.0122 (+0.8838%)

    -0.5420 (-0.4982%)

    +1,917.26 (+3.50%)
  • CMC Crypto 200

    -15.35 (-1.18%)
  • FTSE 100

    -12.90 (-0.18%)
  • Nikkei 225

    +2.00 (+0.01%)

New York Tech Research Team Secures $1.8M NIH Grant to Investigate Vascular Decalcification as Heart Disease Treatment

·4 min read

OLD WESTBURY, N.Y., Jan. 27, 2021 /PRNewswire/ -- A New York Institute of Technology research team led by Olga V. Savinova, Ph.D., assistant professor of biomedical sciences at New York Institute of Technology College of Osteopathic Medicine (NYITCOM), has secured a five-year grant from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute. The $1.8 million grant, which includes a first-year award of $342,675, will support research to improve the understanding of atherosclerosis (hardening of the arteries) and deliver a new treatment for heart disease.

NIH grant supports biomedical research that may lead to a new treatment for heart disease.

According to the Centers for Disease Control and Prevention, more than 30 million U.S. adults have been diagnosed with heart disease, which also causes one in every four deaths. Researchers have long believed that atherosclerosis is a risk factor in predicting heart disease-related illness and death. The buildup of calcium salts in blood vessel tissue, known as vascular calcification, is considered an atherosclerosis hallmark, but it is unclear whether calcification causes atherosclerosis or is simply a byproduct. If it is a risk factor, treatments targeting calcification may prevent millions of future heart disease cases and fatalities.

The team will use mouse and computer models to investigate whether vascular calcification contributes to the development of atherosclerosis and, if so, whether a decalcification treatment can correct and prevent it.

"Our overarching goal is to gain a better understanding of how calcification impacts the onset, progression, and treatment of atherosclerosis," said Savinova, who also received a 2018 NIH grant to examine vascular calcification in chronic kidney disease. "We believe calcification is a risk factor for atherosclerosis and one that can be corrected. By inhibiting vascular calcification caused by overactive phosphatase, we may be able to provide a therapy for atherosclerosis."

Savinova's team has collected data that suggests the enzyme phosphatase is responsible for vascular calcification. Their research shows that when a surplus of phosphatase exists in combination with high lipid levels, lipids are retained in the blood vessels, accelerating vessel hardening. Consequently, if the overactive gene responsible for the surplus can be "turned down," preventing its ability to cause calcification, atherosclerosis may also be treated.

Computational models will map the blood flow impact of increased calcification in mice with high lipid levels. After administering an inhibitor to mitigate excess enzyme activity, the team will monitor for reduced arterial stress. If their approach is successful, it could also prevent harmful changes in the area of the heart containing the aortic valve, which is critical for proper circulation.

Other New York Tech contributors include Dorinamaria Carka, Ph.D., assistant professor of mechanical engineering, who will lead computer simulations studies on blood flow dynamics, Brian Beatty, Ph.D., associate professor of anatomy, and Maria Plummer, M.D., pathologist and associate professor of clinical specialties. Jose Luis Millan, Ph.D., human genetics professor at the Sanford Burnham Prebys Medical Discovery Institute, is also involved.

The NIH, part of the U.S. Department of Health and Human Services, is the largest biomedical research agency in the world. The grant was supported by the NIH National Heart, Lung, and Blood Institute under Award Number R01HL149864. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About New York Tech

New York Institute of Technology offers 90 undergraduate, graduate, and professional degree programs in more than 50 fields of study, including computer science, data, and cybersecurity; biology and biomedical studies; architecture and design; engineering; health professions and medicine; IT and digital technologies; management; communications and marketing; education and counseling; and energy and sustainability. A nonprofit, independent, private, and nonsectarian institute of higher education, New York Institute of Technology welcomes more than 9,000 students worldwide. The university has campuses in New York City (Manhattan) and Long Island (Old Westbury), New York; Jonesboro, Arkansas; and Vancouver, British Columbia, as well as programs around the world.

New York Institute of Technology embraces its mission to provide career-oriented professional education, give all qualified students access to opportunity, and support research and scholarship that benefit the larger world. More than 107,000 alumni comprise an engaged network of doers, makers, and innovators prepared to change the world, solve 21st-century challenges, and reinvent the future.

Media Contact:
New York Tech Media Relations


View original content:http://www.prnewswire.com/news-releases/new-york-tech-research-team-secures-1-8m-nih-grant-to-investigate-vascular-decalcification-as-heart-disease-treatment-301216319.html

SOURCE New York Institute of Technology